Nutlin-3

目录号:S1061

Nutlin-3 Chemical Structure

Molecular Weight(MW): 581.5

Nutlin-3是一种有效的,选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂,无细胞试验中IC50为90 nM;可稳定p53缺陷细胞中的p73。

规格 价格 库存 购买数量  
RMB 1515.15 现货
RMB 900.36 现货
RMB 1407.13 现货
RMB 3026.07 现货
RMB 7939.67 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck该产品发表文献12篇:

客户使用该产品的5个实验数据:

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell Death Dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • J Cell Physiol, 2018, 233(9):7424-7434. Nutlin-3 purchased from Selleck.

    Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

  • d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

产品安全说明书

Mdm2抑制剂选择性比较

生物活性

产品描述 Nutlin-3是一种有效的,选择性Mdm2(它自身和p53的环指依赖性泛素蛋白连接酶)拮抗剂,无细胞试验中IC50为90 nM;可稳定p53缺陷细胞中的p73。
靶点
Mdm2 [5]
(Cell-free assay)
180 nM
体外研究

Nutlin-3有效抑制MDM2-p53相互作用,IC50 为 90 nM, 导致p53通路激活。Nutlin-3 处理含野生型p53的细胞,如HCT116, RKO 和SJSA-1,诱导MDM2 和p21表达, 且具有有效的抗增殖活性,IC50 为~1.5 μM, 但是作用于含突变型p53的细胞系 SW480和 MDA-MB-435没有效果。10 μM Nutlin-3处理 SJSA-1细胞48小时,显著诱导caspase依赖的细胞凋亡,凋亡达~45%。虽然Nutlin-3也抑制人皮肤 (1043SK) 和小鼠胚胎 (NIH/3T3) 的生长和活力,IC50分别为2.2 μM 和1.3 μM, 10 μM Nutlin-3处理一周后仍保留细胞活力,而3 μM Nutlin-3 处理SJSA-1细胞后,细胞则无活力。[1] Nutlin-3 不诱导p53在关键丝氨酸残基的磷酸化,在特定DNA结合序列没有区别,且与基因毒性药物Doxorubicin和Etoposide诱导的磷酸化p53相比, 使p53靶点基因转活,说明 p53 在关键丝氨酸残基的磷酸化对转录激活和凋亡是非必需的。[2] 虽然与MDM2相比,Nutlin-3 与MDMX 结合的效率低一点, Nutlin-3作用于视网膜母细胞瘤细胞(Weri1),能抑制MDMX–p53相互作用,且诱导 p53通路,IC50为0.7 μM。[3] 30 μM Nutlin-3作用于无野生型p53的细胞,也扰乱内源性p73-HDM2 相互作用,且增强p73稳定性和促凋亡活性, 导致细胞生长受抑制,和诱导凋亡。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NEnFcpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYe1xsDPxE1? MoLSOFjDqGh? NGXjU3JjdG:la4OgNlcuV0iFLXnu[JVk\WRiY3XscEBxem:uaX\ldoF1cW:wIHPvcZBiemGkbHWgeI8hfGijdDDv[kBj[XOjbDDs[ZZmdHN? NXG1NmhKOjZ|NUC1OlU>
NP69 NVTzW5NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7YVpdKSzVyPUOxMlY6yrF{LkW0JO69VQ>? NUT6NIhVOjZ{NUK1O|U>
NP460 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPFTWM2OD1{Mj64OeKyOS5zODFOwG0> MVeyOlI2OjV5NR?=
C666-1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrHWnBKSzVyPUG5Mlk2yrF6LkmzJO69VQ>? NGfaTZczPjJ3MkW3OS=>
C666-1 NYiz[mtzS2WubDDWbYFjcWyrdImgRZN{[Xl? NXTISlAyOTBiwsXN NIS3XXU1QCCq Mn[3SG1UVw>? NUTHb5due2Wwc3n0bZpmeyCFNk[2MVEh[2WubIOgeI8hfGinIHP5eI91d3irYzDl[oZm[3Rib3[gZ4l{eGyjdHnu MXiyOlI2OjV5NR?=
C666-1  MUnGeY5kfGmxbjDBd5NigQ>? MnPlNVAhyrWP NYPLT5dKOjRiaB?= M3rteWROW09? NXjXdXJ1[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ M2r1OlI3OjV{NUe1
C666-1 M1;tfGFxd3C2b4Ppd{BCe3OjeR?= NH\jRmQyOCEEtV2= MXG0PE84OiCq Ml72SG1UVw>? MWrz[Y5{cXSrenXzJGM3PjZvMTDj[YxteyC2bzDjbZNxdGG2aX6tbY5lfWOnZDDhdI9xfG:|aYO= NV;aWZhwOjZ{NUK1O|U>
A549 NF7iTplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYKyOEBp Mmm3TWM2OD1zNz62PEDDuSB2LkWyJO69VQ>? M{TkPFI3OTJ3MkOw
A549-NTC MoTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jCPFI1KGh? M{jXVmlEPTB;MUmuOFIhyrFiMT65OkDPxE1? MYCyOlEzPTJ|MB?=
A549-920 Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnQNlQhcA>? MUTJR|UxRTN|Lki1JOKyKDRwOESg{txO MVSyOlEzPTJ|MB?=
CRL-5908 Mn\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;ROVI1KGh? NGjU[o5KSzVyPUO4MlcyKMLzIEKuOFMh|ryP NEXvO3gzPjF{NUKzNC=>
L6 NIXyV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVixNOKh|ryPwrC= Ml;lNlQwPDhxN{KgbC=> M2LqO2ROW09? MVTpcohq[mm2czDj[YxteyCycn;sbYZmemG2aX;uJIFv\CCmaX\m[ZJmdnSrYYTpc44> M3rlTFI2QDdzN{m0
C2C12 NFvI[JVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\hOFExyqEQvF5CpC=> MlzhNlQwPDhxN{KgbC=> NIHzSGxFVVOR NInoO5ZqdmirYnn0d{Bk\WyuczDwdo9tcW[ncnH0bY9vKGGwZDDkbYZn\XKnboTpZZRqd25? MnS5NlU5PzF5OUS=
MCF-7  NHriWYhHfW6ldHnvckBCe3OjeR?= MkSyNVDDqM7:TR?= MnTwSG1UVw>? NH\yfnBqdmirYnn0d{BkgWOuaX6gSFEh[W6mIFTpZ4VzyqB? MXSyOVcxOjdyMx?=
DU4475  M17QRWZ2dmO2aX;uJGF{e2G7 MVG1M|ExNzJyIN88US=> NITnZm4zPMLiaB?= MkjC[I94dnKnZ4XsZZRmeyCWb3PhMVEh\G:|ZTDk[ZBmdmSnboTsfS=> NXvVSoZnOjV3NEexO|Q>
SMMC-7721 MnHRSpVv[3Srb36gRZN{[Xl? MlTINVAh|ryP MmLGOFghcA>? MUDEUXNQ M1PIO4NifXOnczDEUmEhTFOEIHThcYFo\Q>? M3XrV|I2PTR2M{[x
SMMC-7721 NEPteJVHfW6ldHnvckBCe3OjeR?= MYmxNEDPxE1? MVK0PEBp M{DTSGROW09? MXjpcoR2[2W|IITo[UBkcHKxbXH0bY4u[m:3bnSgdJJwfGWrbjDJSmkyPiC2bzDwZZJ1cWGubImgcI9k[WyrenWgbY4hfGinIHP5eI9xdGG|bdMg MX[yOVU1PDN4MR?=
SMMC-7721 MlH4SpVv[3Srb36gRZN{[Xl? MknlNVAh|ryP M{nkU|Q5KGh? MVzEUXNQ NYH4fmhzcW6lcnXhd4V{KHSqZTDlfJBz\XO|aX;uJIxmfmWuIH;mxsBKTk6EMdMgcXJPSQ>? MVGyOVU1PDN4MR?=
SMMC-7721 NWq2NHZiTnWwY4Tpc44hSXO|YYm= M1K3dlExKM7:TR?= M2Pmc|M3KGh? NUm2SYJ1TE2VTx?= MnLPZ4F2e2W|IITo[UBm[3SxcHnjJIV5eHKnc4Ppc44hd2ZiSV\JNVY> NYWyRWdPOjV3NESzOlE>
MCF-7 M2fTXWZ2dmO2aX;uJGF{e2G7 NVfybo9nOTEEoN88US=> NUD1NVdMOC1{NDDo MmPXbY5lfWOnczDwOVMh[W6mIICyNU9EcXBz MUeyOVQ5OjN5Mx?=
OVCAR10 NUe3V5lTTnWwY4Tpc44hSXO|YYm= MXWxNOKh|ryP NInjflkzOWkEoB?= M{DjXWROW09? NUL0NnFJcW6lcnXhd4V{KHB3MzDwdo91\WmwIHzleoVtew>? M4nMd|I2PDJ4NUS4
NCI-H23 NFXPfIJHfW6ldHnvckBCe3OjeR?= NF;UWY4yOMLizszN MnPSNlFpyqB? NFLoNmVFVVOR M1\KTolv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> MnnwNlU1OjZ3NEi=
A2780 MWHGeY5kfGmxbjDBd5NigQ>? MmPkNVDDqM7:TR?= MnXPNlFpyqB? NVG4bpVqTE2VTx?= M4fxO4lv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> M1HNRVI2PDJ4NUS4
NCI-H23 M4[zSmZ2dmO2aX;uJGF{e2G7 MmjzNVDDqM7:TR?= MUSyNYjDqA>? NVzCellsTE2VTx?= NInZfo1l\WO{ZXHz[ZMhfGinIF\vfG0yKGyndnXsdy=> MnrzNlU1OjZ3NEi=
A2780 NF65bHdHfW6ldHnvckBCe3OjeR?= NInaelQyOMLizszN MUeyNYjDqA>? NGT1dndFVVOR NU[0Z|R7\GWlcnXhd4V{KHSqZTDGc5hOOSCuZY\lcJM> M4ryPFI2PDJ4NUS4
HCT116  M2TTWGZ2dmO2aX;uJGF{e2G7 MUSxNEDDvU1? NYnqN|hoOjRiaB?= NYfG[Wxl[2G3c3XzJIEheDV|LXTldIVv\GWwdDD0[ZRz[XCub3nkJGcyNWG{cnXzeEBqdiCmaYDsc4llKEiFVEGxOkBkdG:wZYOgSFMh[W6mIFS4 NIPa[GwzPTN6MEC1OS=>
MCF-10CA1a NUDHeIRrTnWwY4Tpc44hSXO|YYm= M2j4dVExyqEQvF2= Ml7ZOFghcA>? NXTY[5BPTE2VTx?= M2KwcIlvcGmkaYTzJIJie2GuIHnueoF{cW:wIHHu[EBz\WS3Y3XkJHRITi4QskOtbY5lfWOnZDDpcpZie2mxbjD0c{Bj[XOjbDDs[ZZmdHN? M1fCcFI2OjV5N{K5
MCF-10A1  MXzGeY5kfGmxbjDBd5NigQ>? NIfDSFIyOMLizszN MkjTNlQwPDhiaB?= NUnEWFVwTE2VTx?= MlvzbY5pcWKrdIOgcYloemG2aX;uJI9nKG6xcn3hcEBjemWjc4Sg[ZBqfGinbHnhcOKh M2LVclI2OjV5N{K5
MCF-10CA1a MnXNSpVv[3Srb36gRZN{[Xl? MkTXNVDDqM7:TR?= M3jLRlI1KGh? MXHEUXNQ MV\k[YNz\WG|ZYOgeIhmKFSJRj5OtlMucW6mdXPl[EBuWk6DIHzleoVteyCxZl3NVFItyqCPTWC5MEBidmUEoHnueIVoemmwwrFOtuKhOw>? NELhSoczPTJ3N{eyPS=>
MCF-10CA1a MXnGeY5kfGmxbjDBd5NigQ>? M4PuNVExyqEQvF2= NUPIR|hWOjRiaB?= NH\nUWRFVVOR MV7pcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? MVSyOVI2Pzd{OR?=
SK-BR-7 NHLkfYhHfW6ldHnvckBCe3OjeR?= NV\LcGhOOTEEoN88US=> M3;Id|I1KGh? MoPCSG1UVw>? MX;pcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? M122cFI2OjV5N{K5
SUM102PT MVnGeY5kfGmxbjDBd5NigQ>? MYqxNOKh|ryP M{DPeVI1KGh? MnX4SG1UVw>? MXvpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NGTBV48zPTJ3N{eyPS=>
RAW 264.7 M{TYfmZ2dmO2aX;uJGF{e2G7 NHfSdY8yOMLizszN NVKwUmRFOzBibXnu MoTwdJJmfmWwdIOgeIhmKHB3MzDy[YR2[3Srb36gbY4hemW|cH;ud4UhfG9iTGDT NGHSOnczPTF5MkW0Oy=>
RAW 264.7 MX;GeY5kfGmxbjDBd5NigQ>? Mnm4NVDDqM7:TR?= M2PNN|MxKG2rbh?= NGDHXFhz\WS3Y3XzJJRp\SCOUGOtZZVodWWwdHXkJJRp\SCQRj5OvmIhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIFkfGm4aYT5 M{PTPVI2OTd{NUS3
RAW 264.7 NHrIPXdHfW6ldHnvckBCe3OjeR?= M2T4cVExyqEQvF2= MXezNEBucW5? Ml\RbY5pcWKrdIOgUHBUNWmwZIXj[YQhVk9icILv[JVkfGmxbtMg M3LxO|I2OTd{NUS3
MCF7  MmTBR4VtdCCYaXHibYxqfHliQYPzZZk> NXKzWHF2Oi53INM1US=> NYmzfZFCPSCm MYXEUXNQ NEDLOXR{\W6|aYTpfoV{KE2FRkegeI8hWEGUUDDpcohq[mm2aX;u NFK1PGUzPTB6NUmwNi=>
MCF7  MVfGeY5kfGmxbjDBd5NigQ>? MU[yMlUhyrWP MUG0PEBp NUjKOI41TE2VTx?= MofW[IVkemWjc3XzJJRp\SCqb33vcI9od3W|IFTTRkBz\XCjaYKg[pJmeXWnbnPp[ZM> M1LaPVI2ODh3OUCy
ACHN NWLaNW1[S2WubDDWbYFjcWyrdImgRZN{[Xl? MYGwMlUuOTBizszN M1TGdlAuPiCm MXjEUXNQ NV7sbIhJcW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MnXHNlUxPjd5OEe=
Caki-2 MVnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NGS5RlgxNjVvMUCg{txO MY[wMVYh\A>? M1zufWROW09? MUfpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NEDxPIozPTB4N{e4Oy=>
A498 NGK5XnVE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MoPXNE42NTFyIN88US=> M2O0VVAuPiCm NFrNcotFVVOR NH:0VnpqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MnyyNlUxPjd5OEe=
115 NW[0TZRFS2WubDDWbYFjcWyrdImgRZN{[Xl? M3HYUlAvPS1zMDFOwG0> NYDPVmRZOC14IHS= MnrESG1UVw>? MWXpcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NFfkOlQzPTB4N{e4Oy=>
117 M13icGNmdGxiVnnhZoltcXS7IFHzd4F6 M3j1bVAvPS1zMDFOwG0> M3fBV|AuPiCm M2\HS2ROW09? NYfpSmlncW6qaXLpeJMheHKxbHnm[ZJifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= M1vBfVI2ODZ5N{i3
ACHN MYLGeY5kfGmxbjDBd5NigQ>? NXzlOmVtOC53L{GvOUDPxE1? MXy0PEBp MUnEUXNQ MkPVcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? NUj0OGl2OjVyNke3PFc>
Caki-2 M2HsPWZ2dmO2aX;uJGF{e2G7 M3fnZ|AvPS9zL{Wg{txO MXu0PEBp NFLzUnhFVVOR NEnGTndt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NFHWeFgzPTB4N{e4Oy=>
A498 NITSbIZHfW6ldHnvckBCe3OjeR?= NFnye5YxNjVxMT:1JO69VQ>? Ml21OFghcA>? NFfBUoxFVVOR MYDs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MXuyOVA3Pzd6Nx?=
115 MVvGeY5kfGmxbjDBd5NigQ>? NV\G[m12OC53L{GvOUDPxE1? NVS5[Fg2PDhiaB?= NFH4T|JFVVOR NE\jWWFt\WGmczD0c{BqdmO{ZXHz[YQh\XiycnXzd4lwdiCxZjDwOVMh[W6mIIPvcYUheDV|IIThdodmfCCpZX7ld|ohVUSPMjygZY5lKHB{MR?= NWXhbI13OjVyNke3PFc>
ACHN M2rxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK3XnM2KM7:TR?= MoHnOFghcA>? M1rDRmROW09? NXPOb3NzcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh M1[1eFI2ODZ5N{i3
Caki-2 NY\BNWh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkD4OUDPxE1? NUPVU2p5PDhiaB?= MX;EUXNQ NE[4R3NqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> MofiNlUxPjd5OEe=
A498 NWi1dVBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\sTVQ2KM7:TR?= NHThXlI1QCCq M4nY[WROW09? NGLMdoVqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> Mnv2NlUxPjd5OEe=
115 M{DkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLtXFM2KM7:TR?= Mn7rOFghcA>? NVLXVWNLTE2VTx?= NEXueFBqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> M3[1UFI2ODZ5N{i3
ACHN M3zYfGZ2dmO2aX;uJGF{e2G7 MlPNOUDPxE1? MUK0PEBp MoTaSG1UVw>? MlTTbY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NXrPNoduOjVyNke3PFc>
Caki-2 NVP5NWNbTnWwY4Tpc44hSXO|YYm= MXO1JO69VQ>? MV20PEBp Mon5SG1UVw>? MU\pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi Mni4NlUxPjd5OEe=
A498 Ml:4SpVv[3Srb36gRZN{[Xl? MoDzOUDPxE1? MkS3OFghcA>? NVfzSlR6TE2VTx?= M1nIXIlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NYfWdYZ[OjVyNke3PFc>
115 MYnGeY5kfGmxbjDBd5NigQ>? Mmr0OUDPxE1? M2mxOVQ5KGh? MVHEUXNQ M4fIOYlv\HWlZYOgdFU{NWSncHXu[IVvfCC|ZX7ld4NmdmOnwrC= NIrXWIozPTB4N{e4Oy=>
MOLM-13 NUT1WJI2TnWwY4Tpc44hSXO|YYm= NVjv[5VEPsLizszN M4HhclAuQCCq MnfXSG1UVw>? MVnpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyNUOsJG1FVTJuIICyNUBidmRiYXPleJlt[XSnZDDwOVM> M1vQZ|I1QDh3MEiy
MOLM-13 MojvSpVv[3Srb36gRZN{[Xl? MXW2xsDPxE1? MVi2JIg> MYnEUXNQ NWX1dXVW\W6qYX7j[ZMhfGinIHHj[ZR6dGG2aX;uJI9nKGirc4TvcoUhUDKEIHHu[EBp\WG2IIPoc4NsKHC{b4TlbY5{KEi|cEK3JIFv\CCKc4C5NC=> NWLFNFdtOjR6OEWwPFI>
HepG2 NXu3VnBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3XOPFczKGh? M2jMdGROW09? MoDsTWM2OD1|NT64OkDDuSB{Lkmg{txO MUKyOFg5PDhyOR?=
HepG2/As M2XsXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M375[lczKGh? NIr5TW1FVVOR M1PBNGlEPTB;NkiuNVMhyrFiOT62JO69VQ>? MnjnNlQ5QDR6MEm=
SMMC7721 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfxbGQ4OiCq M3\XSmROW09? MXHJR|UxRTNzLkK4JOKyKDRwMjFOwG0> NIXidpYzPDh6NEiwPS=>
SMMC7721/Ac M17DWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSyR|FVPzJiaB?= MYrEUXNQ MkPxTWM2OD13NT6yNUDDuSB3LkCzJO69VQ>? MlToNlQ5QDR6MEm=
Huh-7 M2\jPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlS4O|IhcA>? MlH5SG1UVw>? MYfJR|UxRTN|Lkm2JOKyKDNwOTFOwG0> NU\XOYo5OjR6OES4NFk>
Hep3B NIPwNXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NET3PW44OiCq MoSxSG1UVw>? M2fNRWlEPTB;MkCuNVghyrFiMT64OEDPxE1? MYGyOFg5PDhyOR?=
HepG2 MWTBdI9xfG:|aYOgRZN{[Xl? Mo\ibY5lfWOnczDhdI9xfG:|aYO= NFLJPZUzPDh6NEiwPS=>
SMMC7721 MljsRZBweHSxc3nzJGF{e2G7 M3T1bolv\HWlZYOgZZBweHSxc3nz NHXxS24zPDh6NEiwPS=>
Huh-7 NWTVe2ZoSXCxcITvd4l{KEG|c3H5 NVW3[5RVcW6mdXPld{BieG:ydH;zbZM> NWf4V2tvOjR6OES4NFk>
Hep3B NYXOTWN1SXCxcITvd4l{KEG|c3H5 MWDpcoR2[2W|IHHwc5B1d3Orcx?= Mn\HNlQ5QDR6MEm=
U2OS  Mon5SpVv[3Srb36gRZN{[Xl? MoPENlAh|ryP MkTNNlQhcA>? M{n1[4lv[3KnYYPld{B1cGVibWLORUBt\X[nbIOgc4bDqEKFTELBNUwhSkOOWF|CpIFv\EKFTGe= NY\0cnFbOjR6NkeyOVk>
AML2 MkHoRZBweHSxc3nzJGF{e2G7 NF;HdZczNzFyIN88US=> NHnLeIwzPC92ODDo NFvaN3dqdmS3Y3XzJIFxd3C2b4Ppdy=> NWDkSWgxOjR4NUm3OFk>
MOML13 MWHBdI9xfG:|aYOgRZN{[Xl? M3uz[VIwOTBizszN M4jwd|I1NzR6IHi= MmHubY5lfWOnczDhdI9xfG:|aYO= MkX5NlQ3PTl5NEm=
AML2 MnrISpVv[3Srb36gRZN{[Xl? Ml\nNVDPxE1? MlfFNk81KGh? NIPHcHFqdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> NH\pNmwzPDZ3OUe0PS=>
AML3 MWHGeY5kfGmxbjDBd5NigQ>? MXyxNO69VQ>? M3fTU|IwPCCq MYXpcoNz\WG|ZYOgeIhmKGyndnXsJI9nKHB3Mx?= MYeyOFY2QTd2OR?=
MOML13 NVTsVllITnWwY4Tpc44hSXO|YYm= MX6xNO69VQ>? M1nQdlIwPCCq M3XEZolv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz NYnUZ5hSOjR4NUm3OFk>
BeWo NETaU|BHfW6ldHnvckBCe3OjeR?= M4W0dlMxKML3TR?= NXHiboV4OjRiaB?= NWLzT2JFcW6lcnXhd4V{KHB3MzygUYRuOixicEKxJIFv\CCSdX3hJIF1KHSqZTDwdo91\WmwIHzleoVt MYiyOFQ6QDF3NB?=
BeWo M{OyNmFxd3C2b4Ppd{BCe3OjeR?= NWXkbHV7OzBiwsXN M4TCd|I1KGh? M1WzXolv[3KnYYPld{BieG:ydH;zbZM> MkjqNlQ1QThzNUS=
OCI Mli3SpVv[3Srb36gRZN{[Xl? Mk[4NVAh|ryP NVXZSVBKOjRiaB?= M2fabJVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= MlSyNlQ1PzN3NkK=
MOLM MVvGeY5kfGmxbjDBd5NigQ>? NFvVOWUyOCEQvF2= NG\JNFYzPCCq NFzl[3R2eHKnZ4XsZZRmeyC2aHWgV29EWy1zIHX4dJJme3Orb36= MXOyOFQ4OzV4Mh?=
U2OS  MmLCSpVv[3Srb36gRZN{[Xl? MU[yNEDPxE1? NWLTZnR{OjRiaB?= M13iUolv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? M{G5blI1OzZ4MEC3
RKO NV3DNodrTnWwY4Tpc44hSXO|YYm= NHjp[Y4zOCEQvF2= M2noelI1KGh? NESySnBqdmO{ZXHz[ZMhfGinIHzleoVteyCxZjD0bIUhUE9vMTDwdo91\WmwIHHzJJdmdGxiYYOgeIhmKHB3MzDwdo91\Wmw M2jUUVI1OzZ4MEC3
U2OS  NYruUVJJTnWwY4Tpc44hSXO|YYm= MnjnNlAh|ryP M37DO|I1KGh? MkPlbY5lfWOnczDIU{0yKGW6cILld5Nqd25iYYSgeIhmKGyndnXsJI9nKHS{YX7zZ5JqeHSrb36= NHPHR5ozPDN4NkCwOy=>
RKO M{eyemZ2dmO2aX;uJGF{e2G7 MYeyNEDPxE1? MYCyOEBp NEXMPXBqdmS3Y3XzJGhQNTFiZYjwdoV{e2mxbjDheEB1cGVibHX2[Ywhd2ZidILhcpNkemmydHnvci=> M1PwV|I1OzZ4MEC3
SMMC-7721  MmLXR4VtdCCYaXHibYxqfHliQYPzZZk> MVWxMlI2NTJyIN88US=> M3PvdVI1NzR6L{eyJIg> MXXEUXNQ NXzPUI5scW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGSxc3WgZY5lKHSrbXWg[IVx\W6mZX70cJk> MU[yOFI5PjNzMh?=
HuH-7 MWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MYexMlI2NTJyIN88US=> MkjMNlQwPDhxN{KgbC=> NVvGbnJuTE2VTx?= NFfydJVqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MlvXNlQzQDZ|MUK=
SMMC-7721  MXnBdI9xfG:|aYOgRZN{[Xl? NX[0UHg3OjBizszN MmC5OFghcA>? M2TEV2ROW09? NE\1OIJqdmS3Y3XzJIFxd3C2b4Ppdy=> MWqyOFI5PjNzMh?=
HuH-7 Ml[zRZBweHSxc3nzJGF{e2G7 M1fSelIxKM7:TR?= M{HqbFQ5KGh? NY[wPJVETE2VTx?= NUHteZRFcW6mdXPld{BieG:ydH;zbZM> MnPINlQzQDZ|MUK=
SMMC-7721  NUDFNWNjTnWwY4Tpc44hSXO|YYm= M2nPRVExKM7:TR?= MYmzOkBp NGHpeGdFVVOR NYHJU3FK\G:5bj3y[Yd2dGG2ZYOgeIhmKHC{b4TlbY4h\XiycnXzd4lwdiCuZY\lcEBw\iCyaH;zdIhwNVOnckO5Nk1xPTN? M2rINFI1Ojh4M{Gy
HuH-7 MkPaSpVv[3Srb36gRZN{[Xl? M2DXVVExKM7:TR?= M2jyN|M3KGh? MmDPSG1UVw>? MWXkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> M1nX[VI1Ojh4M{Gy
AT2 NGjrfIhHfW6ldHnvckBCe3OjeR?= NVrLTXJJPS9zMDFOwG0> M4D5fIxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li M3nPb|I1OjRyMkCz
REH NIrINGpHfW6ldHnvckBCe3OjeR?= NXjsWItVPS9zMDFOwG0> MnS1cIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NGHYZZAzPDJ2MEKwNy=>
UoCB6 M1LaUWZ2dmO2aX;uJGF{e2G7 MnnoOU8yOCEQvF2= MVrs[YFleyC2bzDhJJN2[nO2YX70bYFtKGGlY4XteYxifGmxbjDv[kB1cGVicEWzJJBzd3SnaX6gZZMhf2WubDDhd{B1cGViZYjwdoV{e2mxbjDv[kBqfHNiZHny[YN1KHSjcnfleJMheDJzLDDNSG0zKGGwZDD0bIUheHKxLXHwc5B1d3SrYzDCRXgh[W6mIGDVUWEheHKxdHXpcpPDqA>? NF7kXWszPDJ2MEKwNy=>
AT2 NWraZYRzS2WubDDWbYFjcWyrdImgRZN{[Xl? MYewMVI2KM7:TR?= NGXRUmlqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 M{nuSVI1OjRyMkCz
REH MXPD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NWHId4hZOC1{NTFOwG0> NUfLdmJNcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= M3f1S|I1OjRyMkCz
UoCB6 MXLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWSwMVI2KM7:TR?= MYfpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NXPiTI4zOjR{NECyNFM>
A2780 MUHGeY5kfGmxbjDBd5NigQ>? MWm1M|ExNzJyIN88US=> M1rmbVI1KGh? MUP1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? NGPObnUzPDF|NkG0Oy=>
H460 NFviS5pHfW6ldHnvckBCe3OjeR?= NWLST4hJPS9zMD:yNEDPxE1? M2PzblI1KGh? MmrQeZBz\We3bHH0[ZMheDV|LDDNSG0zNCCyMkGgZY5lKESUNTDwdo91\WmwIHzleoVteyCmb4PlJIRmeGWwZHXueIx6yqB? MkLENlQyOzZzNEe=
Lovo  MYDGeY5kfGmxbjDBd5NigQ>? NV3RVVlyPS9zMD:yNEDPxE1? MkDwNlQhcA>? NVv4R|BMfXC{ZXf1cIF1\XNicEWzMEBOTE1{LDDwNlEh[W6mIFTSOUBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7wrC= NEf5WlYzPDF|NkG0Oy=>
A2780 MkX2RZBweHSxc3nzJGF{e2G7 MlfOOU8yOC9{MDFOwG0> M1\QO|I1KGh? MoXV[Y5p[W6lZYOgZZBweHSxc3nzJIlv\HWldHnvckBjgSCGMk[5TE9GOTl3UjDveoVzKHKqVGLBTWw> NF3LWJkzPDF|NkG0Oy=>
H460 NUnOemdvSXCxcITvd4l{KEG|c3H5 Mn21OU8yOC9{MDFOwG0> NVXIXFM2OjRiaB?= NUSxdlZp\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? NXnuOVNmOjRzM{[xOFc>
Lovo  NUfaVHlSSXCxcITvd4l{KEG|c3H5 NIPjcY42NzFyL{KwJO69VQ>? NFXIUIIzPCCq NX;ib4pw\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? MV2yOFE{PjF2Nx?=

... Click to View More Cell Line Experimental Data

体内研究 Nutlin-3 按200 mg/kg 剂量口服处理,每天两次,持续3周,显著抑制SJAS-1移植瘤生长,抑制达90%, 而Doxorubicin抑制81%肿瘤生长。[1]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:

[1]

+ 展开

Biacore 研究:

在Biacore S51上进行竞争性实验。衍生一系列S传感器芯片CM5,用于固定 PentaHis抗体,为了捕获 His-标记的p53。捕获的水平为~200反应单位(1 反应单位对应于1 pg 蛋白/ mm2)。MDM2蛋白浓度一直维持在300 nM。Nutlin-3 溶于DMSO,浓度为10 mM,然后进一步稀释,在每个MDM2实验样本中产生系列浓度的Nutlin-3。在电泳缓冲液(10 mM Hepes,0.15 M NaCl, 2% DMSO)中25oC下进行实验。在Nutlin-3存在时,计算MDM2-p53结合情况,作为结合百分数, 使用Microsoft Excel计算IC50。
细胞实验:

[1]

+ 展开
  • Cell lines: HCT116, RKO, SJSA-1, SW480, 和 MDA-MB-435
  • Concentrations: 溶于DMSO,终浓度为~ 30 μM
  • Incubation Time: 8, 24, 和 48 小时
  • Method:

    使用不同浓度Nutlin-3处理细胞8, 24和 48 小时。通过实时PCR分析p21 和MDM2基因转录水平,通过Western Blotting分析蛋白水平。通过MTT实验测定细胞活力。 通过末端脱氧核苷酸转移酶调节的脱氧尿苷三磷酸缺口末端标记法(TUNEL)染色,使用流式细胞仪和荧光显微镜测定细胞凋亡。


    (Only for Reference)
动物实验:

[1]

+ 展开
  • Animal Models: 皮下注射 SJSA-1细胞的雌性无胸腺Nu/Nu-nuBR裸鼠
  • Formulation: 在 2% Klucel, 0.5% Tween-80配制中配制
  • Dosages: 200 mg/kg
  • Administration: 口服处理,每天两次
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 581.5
化学式

C30H30Cl2N4O4

CAS号 890090-75-2
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2 Signaling Pathway Map

相关Mdm2产品

Tags: 购买Nutlin-3 | Nutlin-3供应商 | 采购Nutlin-3 | Nutlin-3价格 | Nutlin-3生产 | 订购Nutlin-3 | Nutlin-3代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID